Randomised clinical trial: A comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 3, 2011, Pages 313-322

  Kruis, W ^a   Jonaitis, L ^b   Pokrotnieks, J ^c   Mikhailova, T L ^d   Horynski, M ^e   Batovska M ^f   Lozynsky, Y S ^g   Zakharash, Y ^h   Racz I ⁱ   Kull, K ^j   Vcev, A ^k   Faszczyk, M ^l   Dilger, K ^m   Greinwald, R ^m   Mueller, R ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^c PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^d State Scientific Centre of Coloproctology   (Russian Federation)

^e Centrum Medyczne 'Sopmed' NZOZ   (Poland)

^f Derer 's University Hospital Slovakia   (Slovakia)

^g DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^h BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

ⁱ Petz Aladar County and Teaching Hospital   (Hungary)

^j TARTU UNIVERSITY HOSPITAL   (Estonia)

^k UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^l BARZILAI MEDICAL CENTER   (Israel)

^m Dr Falk Pharma GmbH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 MICROGLOBULIN; CYSTATIN C; MESALAZINE; N ACETYL BETA GLUCOSAMINIDASE;

ADULT; ARTICLE; BODY MASS; CREATININE CLEARANCE; DISEASE ACTIVITY; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SIDE EFFECT; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; REMISSION INDUCTION; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650879471     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04537.x     Document Type: Article

References (21)

1. Sutherland LR, MacDonald JK,. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 2: CD000544.
2. Fockens P, Mulder CJ, Tytgat GN, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol 1995; 7: 1025-30.
3. Hanauer SB, Sninsky C, Robinson M, et al. An oral preparation of mesalazine as long-term maintenance therapy for ulcerative colitis. A randomized placebo-controlled trial. Ann Intern Med 1996; 124: 204-11.
4. Paoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21: 1111-9.
5. Bergman R, Parkes M,. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23: 841-55.
6. Hanauer SB,. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther 2006; 24: 37-40.
7. Shale MJ, Riley SA,. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8.
8. Cohen RD,. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 24: 465-74.
9. Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from (15)Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 2003; 17: 1163-9.
10. Rachmilewitz D,. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-6.
11. Dilger K, Trenk D, Rössle M, et al. A clinical trial on absorption and N-Acetylation of oral and rectal mesalazine. Eur J Clin Invest 2007; 37: 558-65.
12. Dharnidharka VR, Kwon C, Stevens G,. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.
13. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX⢠mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893-902.
14. Dignass AU, Bokemeyer B, Ad AH, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-9.
15. Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010; 138: 1286-96.
16. Kane SV, Accortt NA, Magowan S, et al. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther 2009; 29: 855-62.
17. Lichtenstein GR, Gordon GL, Zakko S, et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis-a 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010; 32: 990-9.
18. Patel H, Barr A, Jeejeebhoy KN,. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009; 23: 170-6.
19. Hofmann W, Regenbogen C, Edel H, et al. Diagnostic strategies in urinalysis. Kidney Int Suppl 1994; 47: S111-4.
20. Gisbert JP, Gonzalez-Lama Y, Mate J,. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007; 13: 629-38. (Pubitemid 46799647)
21. Dilger K, Baumgärtner P, Thomann T,. Once-daily oral mesalazine (1.5 g/day or 3.0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial. Gut 2007; 56 (Suppl. III): A150.